Science, Volume 392, Issue 6803, June 2026.
Assessing the net climate benefits of improved grazing intensity in global rangelands
Science, Volume 392, Issue 6803, Page 1161-1166, June 2026.
Microglia at a key inflection point in Alzheimer’s disease
Nature Medicine, Published online: 11 June 2026; doi:10.1038/s41591-026-04409-3
We analyzed brains from octogenarians and cognitively resilient centenarians to understand why some individuals with substantial Alzheimer’s disease pathology develop dementia whereas others remain cognitively intact. Spatial transcriptomics revealed gene expression changes in discrete tissue domains surrounding amyloid plaques and tau pathology that distinguish early, clinically silent, disease from later stages associated with cognitive decline.
Major Depressive Disorder from a Brain-Body Perspective: Reproducible Central Cardiac Interoception Deficits and Peripheral Autonomic Dysfunctions Dissociate
Brain-heart interaction (BHI) offers a systems-level framework for understanding major depressive disorder (MDD), yet reproducible cross-system markers remain unclear. We aimed to identify reproducible BHI impairments in MDD and clarify their physiological and clinical correlates.
Focused ultrasound ablation for psychiatric disorders
Modern circuit-based neurosurgical interventions address a critical unmet need for patients with treatment-resistant psychiatric illness. Magnetic resonance–guided high-intensity focused ultrasound (HIFU) enables incisionless, millimeter-precision thermoablation via staged sonications with real-time monitoring, reshaping the risk–benefit profile of traditional neurosurgical interventions for psychiatric disorders.Here, we review the clinical evidence for HIFU ablation and contrast it with alternative platforms, including radiofrequency ablation, radiosurgery, laser interstitial thermal therapy, and deep brain stimulation.
Advancing Clinical Translational Research for Profound Autism
Autism Spectrum Disorder (ASD) has emerged as a key battleground in the federal assault on science. US government leaders have systematically ignored expert advice, reanimated baseless claims about the causal role of vaccines, forwarded thinly supported hypotheses blaming ASD on parental behavior, and promoted unsubstantiated treatments. This barrage comes at a time when the prospects for dramatic near-term advances in clinical translation, particularly for the severe end of the ASD spectrum, have never been greater.
Targeting Mu opioid receptor neurons of the habenula to limit naloxone aversion
Opioid use disorder is a chronic, relapsing condition that continues to rise worldwide. Naloxone (Narcan®), an opioid antagonist, reverses overdose but triggers strong negative affect. The neuronal circuits underlying these aversive effects remain unclear. We previously identified mu opioid receptor–expressing habenular neurons (Hb-MOR) as key encoders of negative emotional states and hypothesized that they also mediate naloxone aversion.
Focused Ultrasound Neuromodulation for Substance Use Disorder
Given the prevalence of substance use disorder (SUD), elevated overdose death rates, and limited approved pharmacotherapies for SUD, new treatment approaches are necessary. Neuromodulation is a potential adjunctive treatment for SUD to reduce substance use and risk factors associated with drug use recurrence, such as craving. One form of neuromodulation, focused ultrasound (FUS), has significant potential given that it is non-invasive and capable of targeting subcortical structures implicated in the brain’s reward circuity with great precision.
An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
Digital Health Monitoring and Intervention Suite for Stress in Frontline Nurses: Prospective Cohort Trial
Background: Stress among health care workers (HCWs) contributes to burnout, workforce attrition, and adverse patient outcomes. Although virtual reality (VR), psychoeducation, ecological momentary assessments (EMAs), and wearables have independently shown promise in stress research, no integrated digital suite has combined controlled stress induction, intervention delivery, and longitudinal real-world monitoring in HCWs. Objective: This study aimed to evaluate the feasibility, engagement, and preliminary effectiveness of a multimodal Digital Health Monitoring and Intervention suite for Stress framework integrating VR simulation, psychoeducation, EMAs, and wearable biometrics. We examined (1) the impact of VR simulation and psychoeducation on stress outcomes and (2) associations between physiological and self-reported mental health outcomes. Methods: Ninety-nine nurses (mean age 33.7, SD 8.9 yr, 87% female) were enrolled in 2023. We conducted a single-arm prospective cohort study (NCT05923398). Using convenience sampling, participants were recruited from social media advertisements, flyers, and email notices distributed through professional listservs. Participants completed ≥2-week baseline monitoring, a single VR session (2 runs separated by a brief psychoeducation intervention), and 12-week follow-up. In-VR stress was assessed using the Subjective Units of Distress Scale (SUDS) and 4-item Moral Injury Outcome Scale (MIOS-4), with synchronous heart rate variability. Longitudinal outcomes included weekly and biweekly EMAs alongside 70 wearable-derived features. Paired tests, aligned rank transform ANOVA, and Pearson correlations informed study objectives, with P values adjusted for multiple comparisons. Qualitative content analysis classified emotional responses during and after VR. Results: VR significantly increased subjective stress across checkpoints in both runs, with attenuation in Run B relative to Run A (all <.001). No significant heart rate variability differences were observed between runs (.15). During VR, 92% (91/99) of participants felt stressed, 36% (36/99) reported anxiety or nervousness, and 51% (50/99)‐78% (77/99) endorsed anger, guilt, shame, and/or betrayal. Most (59/99, 60%) HCWs returned to an emotional baseline post-VR, although 12% (12/99) reported lingering distress. Immediate reliable improvements in anger, guilt, shame, and/or betrayal occurred for 50% (50/99)‐75% (74/99) of participants post intervention. Anxiety (mean −0.53, SD 2.34; .03) and stress (mean −3.05, SD 11.35; .01) decreased 2 weeks post intervention, but were not sustained at 12 weeks. Increased sleep restlessness was the only wearable feature showing significant changes (mean 2.46%, SD 5.43; <.001). In-VR stress correlated with 12-week real-world stress (SUDS: =0.57‐0.58; MIOS-4: =0.58‐0.61; all .01). Data completion exceeded 90%, with 71% achieving full compliance. Conclusions: This study moves beyond single-tool interventions to demonstrate the feasibility and preliminary effectiveness of an integrated, multimodal stress platform within a single coordinated framework. This trial demonstrates high engagement, short-term symptom responsiveness, ecological validity, and emotional safety. The framework provides a scalable model for proactive stress identification, skills training, and implementation in high-risk occupational settings. Randomized controlled trials are needed to establish sustained efficacy and optimize deployment for real-world implementation. Trial Registration: ClinicalTrials.gov NCT05923398; https://clinicaltrials.gov/study/NCT05923398 International Registered Report Identifier (IRRID): RR2-10.2196/54180
